Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at B. Riley

Eton Pharmaceuticals (NASDAQ:ETON)‘s stock had its “buy” rating reissued by stock analysts at B. Riley in a research report issued on Wednesday,Benzinga reports. They currently have a $24.00 price target on the stock, up from their prior price target of $21.00. B. Riley’s target price would indicate a potential upside of 64.55% from the stock’s current price.

Several other equities analysts have also recently commented on the stock. Craig Hallum lifted their target price on shares of Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $33.00 target price on shares of Eton Pharmaceuticals in a research report on Wednesday.

Eton Pharmaceuticals Stock Down 0.6 %

ETON stock traded down $0.10 during mid-day trading on Wednesday, reaching $14.59. 81,386 shares of the company traded hands, compared to its average volume of 157,483. The stock has a market cap of $379.95 million, a price-to-earnings ratio of -66.30 and a beta of 1.37. Eton Pharmaceuticals has a fifty-two week low of $3.03 and a fifty-two week high of $18.41. The firm’s 50 day moving average price is $15.45 and its 200 day moving average price is $11.42.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The firm had revenue of $11.65 million for the quarter, compared to analysts’ expectations of $10.53 million. On average, analysts anticipate that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of hedge funds have recently modified their holdings of ETON. Mink Brook Asset Management LLC bought a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $6,071,000. Cannell Capital LLC bought a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth approximately $5,079,000. Wasatch Advisors LP bought a new stake in Eton Pharmaceuticals during the 3rd quarter valued at $1,431,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Eton Pharmaceuticals by 230.5% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock valued at $2,862,000 after acquiring an additional 149,864 shares during the period. Finally, Millennium Management LLC bought a new stake in Eton Pharmaceuticals during the 4th quarter valued at $1,850,000. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.